An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma

Trial Profile

An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma

Completed
Phase of Trial: Phase II

Latest Information Update: 31 May 2018

At a glance

  • Drugs Ibrutinib (Primary)
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Acronyms DAWN
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 31 May 2018 Primary endpoint (Overall response rate) has not been met, according to results published in the Journal of Clinical Oncology.
    • 31 May 2018 Results (n=110) published in the Journal of Clinical Oncology.
    • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top